Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsBritish lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...
In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.
Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.
Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.
In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.
For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.
1.
It Is Cancer in Kate Middleton.
2.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
3.
High levels of traumatic stress found in caregivers of adult cancer patients
4.
An inadvertent loss of weight may be an indication to consult a physician, according to research.
5.
Three out of ten breast cancers detected between screenings, study finds
1.
Functional Iron Reserve Screening Before Clinical Deficiency: Clinical Insights and Evidence-Based Strategies
2.
Molecular Mechanisms of Tumor Extracellular-Matrix Stiffness Sensing
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Clinical Frameworks in Hematology for Better Care
5.
Colon cancer: Risk factors, warning signs and treatment options
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge